Redefining Radial Closure: A New Standard in Vascular Access
The SĀPH device is a radial artery closure system that provides a unique method of creating hemostasis following a catheterization procedure. This patent-pending technology offers investors the opportunity to engage with a truly new standard of care in one of the fastest growing markets in the interventional cardiovascular space.
About us
Transradial Technologies Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device. The device is designed to offer a “fast, safe, and easy-to-use” closure solution for radial artery punctures created during a full range of interventional procedures including cardiac catheterization, percutaneous coronary revascularization, and peripheral angiography/revascularization. Transradial Technologies, Inc. has worldwide and exclusive rights to the technology via an agreement with Transradial Holdings, Inc.
Product & Technology
SĀPH (Suction Activated Patent Hemostasis) – Designed to address the growing market of procedures performed using radial artery access, the SĀPH device uniquely closes the arterial puncture by expanding the artery to create compression with the artery puncture site and the surrounding tissue rather than the traditional method of compressing the artery with a tourniquet around the wrist. The SĀPH device achieves a lower rate of radial artery occlusion, a more comfortable patient experience, and importantly, reduces the workload for recovery staff, (i.e. no intermittent patient monitoring is necessary). First in man testing (17 patients) has been successfully completed. This technology is also well suited to transpedal and distal radial arterial access and potentially femoral venous procedures.